永利3044(中国集团)有限公司官网

SKI II (SphK-I2)是一种合成的、非ATP竞争性的、可口服的鞘氨醇激酶(SphK, SK)抑制剂，IC₅₀值为0.5 μM，但对人蛋白激酶ERK2、PKC-I和脂质激酶PI3K没有抑制作用。SKI II可防止SK催化鞘氨醇-1-磷酸(S1P)生成，抑制细胞增殖，在体内能抑制肿瘤生长。

参考文献

1.French KJ, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9.

2.French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318(2):596-603.

3.Zhu ZA, et al. Reversion of multidrug resistance by SKI-II in SGC7901/DDP cells and exploration of underlying mechanisms. Asian Pac J Cancer Prev. 2012;13(2):625-31.

4.Chiba Y, et al. SKI-II, an inhibitor of sphingosine kinase, ameliorates antigen-induced bronchial smooth muscle hyperresponsiveness, but not airway inflammation, in mice. J Pharmacol Sci. 2010;114(3), 304-310.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃干燥保存，避免反复冻融。